GlassScriptPhysician profile
Pawan K Gupta
NPI 1649287012
$2,654.29
in general payments reported to CMS, 2019-2025
21 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $106 · 2021: $75.67 · 2022: $293 · 2023: $441 · 2024: $601 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140 · Consulting Fee: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.43 |
| Consulting Fee | $270.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $672.44 | 2019-2024 | Velphoro |
| Amgen INC. | $383.64 | 2019-2024 | Evenity, Prolia, Krystexxa |
| Baxter Healthcare | $270.00 | 2023 | Renal - Sharesource |
| Vifor Pharma, INC. | $251.45 | 2019-2025 | Veltassa |
| Genzyme Corporation | $192.93 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $187.56 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $136.96 | 2021-2024 | |
| Opko Pharmaceuticals, LLC | $122.97 | 2019-2024 | Rayaldee |
| Travere Therapeutics, INC. | $114.69 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $56.65 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $55.06 | 2019-2024 | Farxiga |
| Ardelyx, INC. | $38.19 | 2024 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $32.58 | 2025 | |
| Akebia Therapeutics INC | $30.82 | 2022-2025 | Vafseo |
| Mallinckrodt Hospital Products INC. | $19.46 | 2024 | Terlivaz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.31 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $17.87 | 2022 | |
| Aurinia Pharma U.S., INC. | $15.28 | 2022 | |
| Shire North American Group INC | $13.84 | 2019 | |
| Daiichi Sankyo INC. | $12.24 | 2022 | |
| Lilly USA, LLC | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pawan Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.